Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer.
Cancer Rep (Hoboken)
; 7(2): e1952, 2024 02.
Article
in En
| MEDLINE
| ID: mdl-38258341
ABSTRACT
OBJECTIVE:
To investigate the risk factors for gastrointestinal perforation in metastatic colorectal cancer patients receiving bevacizumab.METHODS:
We retrospectively reviewed 217 patients with metastatic colorectal cancer receiving bevacizumab to investigate the risk factors for gastrointestinal perforation. Three patients occurred intestinal perforation after receiving bevacizumab. We analyzed the clinical characteristics of three patients with intestinal perforation.RESULTS:
All patients receiving bevacizumab. Three of 217 patients occurred intestinal perforation after receiving bevacizumab. Patient no. 1 was 70 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation and ultimately died after receiving bevacizumab. Patient no. 2 was 59 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation after receiving bevacizumab, and recovered smoothly after symptomatic treatment. Patient no. 3 was 60 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation and ultimately died after receiving bevacizumab.CONCLUSIONS:
Patients with advanced colorectal cancer receiving bevacizumab are at risk of gastrointestinal perforation. The patient's age, gender and history of bowel obstruction may be associated with gastrointestinal perforation.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Rectal Neoplasms
/
Colorectal Neoplasms
/
Colonic Neoplasms
/
Intestinal Obstruction
/
Intestinal Perforation
Type of study:
Risk_factors_studies
Limits:
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Cancer Rep (Hoboken)
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: